01:31 AM EST, 11/11/2026 (MT Newswires) -- Ypsomed (YPSN.SW) logged 85.5 million francs in net profit for the first half of fiscal 2027, compared with 139.1 million francs a year ago. EPS moved to 6.50 francs from 10.19 francs year over year, a Wednesday filing showed. For the six months ended Sept. 30, net sales from goods and services were 317.6 million francs versus 362.7 million francs previously, the Swiss injection and infusion systems manufacturer added. For fiscal 2027, the company upgraded its sales growth guidance to between 13% and 16%, corresponding to sales of 630 million francs to 650 million francs. The initial sales growth forecast was between 12% and 15%, which represented 625 million francs to 645 million francs in sales. The company also affirmed its total sales target of between 900 million francs and 1.1 billion francs for the fiscal 2029 and fiscal 2030 period.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.